Analyst Reco. Allogene Therapeutics, Inc.

Equities

ALLO

US0197701065

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-06 pm EDT			5-day change	1st Jan Change
3.01 ^USD	-1.95%		+5.99%	-6.23%

Apr. 26	Allogene Therapeutics Gets $15 Million Grant from California Institute for Regenerative Medicine for Cancer Drug Development	MT
Apr. 26	Allogene Therapeutics Receives Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Adjusts Allogene Therapeutics Price Target to $10 From $12, Maintains Buy Rating	Jan. 19	MT
B. Riley Adjusts Allogene Therapeutics' PT to $10 From $15 on Heels of Announced Strategic Shift to Focus on New Study for Large B-cell Lymphoma, Keeps Buy Rating	Jan. 05	MT
JMP Securities Downgrades Allogene Therapeutics to Market Perform From Market Outperform	Jan. 05	MT
Citigroup Starts Allogene Therapeutics With Buy Rating, $7 Price Target	Dec. 08	MT
HC Wainwright Cuts Price Target on Allogene Therapeutics to $12 From $23, Keeps Buy Rating	Nov. 15	MT
JPMorgan Adjusts Allogene Therapeutics Price Target to $9 From $11, Maintains Overweight Rating	23-09-25	MT
Truist Securities Lowers Allogene Therapeutics' Price Target to $18 From $20, Maintains Buy Rating	23-07-11	MT
RBC Lowers Allogene Therapeutics' Price Target to $12 From $15, Keeps Outperform Rating	23-07-07	MT
JMP Securities Adjusts Allogene Therapeutics' Price Target to $15 From $19, Keeps Outperform Rating	23-05-05	MT
Stifel Nicolaus Adjusts Allogene Therapeutics Price Target to $7.50 From $8, Maintains Hold Rating	23-05-04	MT
RBC Capital Adjusts Allogene Therapeutics Price Target to $15 From $22, Maintains Outperform - Speculative Risk Rating	23-04-06	MT
HC Wainwright Adjusts Price Target on Allogene Therapeutics to $23 From $29, Maintains Buy Rating	23-04-04	MT
Bernstein Initiates Allogene Therapeutics at Market Perform With $6 Price Target	23-03-21	MT
JMP Securities Adjusts Price Target on Allogene Therapeutics to $19 From $23, Maintains Market Outperform Rating	23-03-02	MT
Oppenheimer Adjusts Allogene Therapeutics Price Target to $28 From $32, Maintains Outperform Rating	23-03-01	MT
B. Riley Lowers Allogene Therapeutics' Price Target to $15 From $18 Due to Setback in Initiating Potentially Pivotal ALLO-715 Trial, Keeps Buy Rating	23-03-01	MT
Goldman Sachs Adjusts Allogene Therapeutics Price Target to $31 From $35, Maintains Buy Rating	23-03-01	MT
RBC Cuts Price Target on Allogene Therapeutics to $22 From $32 Amid BCMA Delay, Maintains Outperform, Speculative Risk	23-03-01	MT
JPMorgan Upgrades Allogene Therapeutics to Overweight From Neutral, Adjusts Price Target to $11 From $20	23-01-24	MT
Baird Upgrades Allogene Therapeutics to Outperform From Neutral, Price Target at $12	23-01-06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Allogene Therapeutics, Inc.

Equities

ALLO

US0197701065

Analyst Reco.

Filters